Saturday, July 12, 2008

FDA lifts clinical hold on YM BioSciences' AeroLEF

MISSISSAUGA, ON, Jun 19, 2008

AeroLEF Division

YM BioSciences Inc. (AMEX: YMI, TSX: YM, AIM: YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced that the Clinical Hold imposed by the US Food and Drug Administration (FDA) on the development of YM's AeroLEF has been lifted. The lifting of this Hold permits YM to resume the expansion into the US of the Phase II clinical development of AeroLEF.

AeroLEF is being developed as a novel and effective approach to the management of acute pain by delivering a proprietary formulation of inhaled, nebulized, free-and-liposome-encapsulated fentanyl. The free fentanyl results in rapid onset of analgesia while the liposome-encapsulated fentanyl produces the unique extended duration of pain relief. The FDA cleared a Phase II protocol in June 2007 to proceed with AeroLEF's first trial in the US, however, immediately prior to the End-of-Phase II meeting scheduled and held in January 2008, the FDA imposed a Clinical Hold, now lifted.

Source: FOX business news

http://www.foxbusiness.com/story/markets/industries/health-care/ym-biosciences-announces-fda-lifts-clinical-hold-aerolefr-clearance-phase-ii/-878661720